230 related articles for article (PubMed ID: 38579000)
1. Human brain glycoform coregulation network and glycan modification alterations in Alzheimer's disease.
Zhang Q; Ma C; Chin LS; Pan S; Li L
Sci Adv; 2024 Apr; 10(14):eadk6911. PubMed ID: 38579000
[TBL] [Abstract][Full Text] [Related]
2. Human brain glycoform co-regulation network and glycan modification alterations in Alzheimer's disease.
Zhang Q; Ma C; Chin LS; Pan S; Li L
bioRxiv; 2023 Nov; ():. PubMed ID: 38014218
[TBL] [Abstract][Full Text] [Related]
3. Glycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer's Disease Brain.
Suttapitugsakul S; Stavenhagen K; Donskaya S; Bennett DA; Mealer RG; Seyfried NT; Cummings RD
Mol Cell Proteomics; 2022 Dec; 21(12):100433. PubMed ID: 36309312
[TBL] [Abstract][Full Text] [Related]
4. Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer's disease.
Zhang Q; Ma C; Chin LS; Li L
Sci Adv; 2020 Oct; 6(40):. PubMed ID: 33008897
[TBL] [Abstract][Full Text] [Related]
5. Multilayered N-Glycoproteome Profiling Reveals Highly Heterogeneous and Dysregulated Protein N-Glycosylation Related to Alzheimer's Disease.
Fang P; Xie J; Sang S; Zhang L; Liu M; Yang L; Xu Y; Yan G; Yao J; Gao X; Qian W; Wang Z; Zhang Y; Yang P; Shen H
Anal Chem; 2020 Jan; 92(1):867-874. PubMed ID: 31751117
[TBL] [Abstract][Full Text] [Related]
6. N-glycan and Alzheimer's disease.
Kizuka Y; Kitazume S; Taniguchi N
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2447-2454. PubMed ID: 28465241
[TBL] [Abstract][Full Text] [Related]
7. In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease.
Chen Z; Yu Q; Yu Q; Johnson J; Shipman R; Zhong X; Huang J; Asthana S; Carlsson C; Okonkwo O; Li L
Mol Cell Proteomics; 2021; 20():100081. PubMed ID: 33862227
[TBL] [Abstract][Full Text] [Related]
8. Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder.
Butterfield DA; Owen JB
Proteomics Clin Appl; 2011 Feb; 5(1-2):50-6. PubMed ID: 21280237
[TBL] [Abstract][Full Text] [Related]
9. Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
Tena J; Maezawa I; Barboza M; Wong M; Zhu C; Alvarez MR; Jin LW; Zivkovic AM; Lebrilla CB
Mol Cell Proteomics; 2022 Nov; 21(11):100427. PubMed ID: 36252735
[TBL] [Abstract][Full Text] [Related]
10. Glycoproteomics of a Single Protein: Revealing Tens of Thousands of Myozyme Glycoforms by Hybrid HPLC-MS Approaches.
Di Marco F; Blöchl C; Esser-Skala W; Schäpertöns V; Zhang T; Wuhrer M; Sandra K; Wohlschlager T; Huber CG
Mol Cell Proteomics; 2023 Sep; 22(9):100622. PubMed ID: 37478974
[TBL] [Abstract][Full Text] [Related]
11. Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery.
Gizaw ST; Ohashi T; Tanaka M; Hinou H; Nishimura S
Biochim Biophys Acta; 2016 Aug; 1860(8):1716-27. PubMed ID: 26968461
[TBL] [Abstract][Full Text] [Related]
12. Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment.
Lundström SL; Yang H; Lyutvinskiy Y; Rutishauser D; Herukka SK; Soininen H; Zubarev RA
J Alzheimers Dis; 2014; 38(3):567-79. PubMed ID: 24028868
[TBL] [Abstract][Full Text] [Related]
13. The N-glycan profile in cortex and hippocampus is altered in Alzheimer disease.
Gaunitz S; Tjernberg LO; Schedin-Weiss S
J Neurochem; 2021 Oct; 159(2):292-304. PubMed ID: 32986846
[TBL] [Abstract][Full Text] [Related]
14. HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.
García-Ayllón MS; Botella-López A; Cuchillo-Ibañez I; Rábano A; Andreasen N; Blennow K; Ávila J; Sáez-Valero J
Mol Neurobiol; 2017 Jan; 54(1):188-199. PubMed ID: 26738850
[TBL] [Abstract][Full Text] [Related]
15. Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment.
Schedin-Weiss S; Gaunitz S; Sui P; Chen Q; Haslam SM; Blennow K; Winblad B; Dell A; Tjernberg LO
FEBS J; 2020 Aug; 287(15):3221-3234. PubMed ID: 31889402
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer's disease.
Tang X; Tena J; Di Lucente J; Maezawa I; Harvey DJ; Jin LW; Lebrilla CB; Zivkovic AM
Sci Rep; 2023 May; 13(1):7816. PubMed ID: 37188790
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a Unique Tetrasaccharide and Distinct Glycoproteome in the O-Linked Protein Glycosylation System of Neisseria elongata subsp. glycolytica.
Anonsen JH; Vik Å; Børud B; Viburiene R; Aas FE; Kidd SW; Aspholm M; Koomey M
J Bacteriol; 2016 Jan; 198(2):256-67. PubMed ID: 26483525
[TBL] [Abstract][Full Text] [Related]
18. Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation.
Yang Q; An Y; Zhu S; Zhang R; Loke CM; Cipollo JF; Wang LX
ACS Chem Biol; 2017 Jun; 12(6):1665-1673. PubMed ID: 28452462
[TBL] [Abstract][Full Text] [Related]
19. High-resolution glycoform profiling of intact therapeutic proteins by hydrophilic interaction chromatography-mass spectrometry.
Domínguez-Vega E; Tengattini S; Peintner C; van Angeren J; Temporini C; Haselberg R; Massolini G; Somsen GW
Talanta; 2018 Jul; 184():375-381. PubMed ID: 29674057
[TBL] [Abstract][Full Text] [Related]
20. In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimer's Disease (AD) Patients.
Chen Z; Wang D; Yu Q; Johnson J; Shipman R; Zhong X; Huang J; Yu Q; Zetterberg H; Asthana S; Carlsson C; Okonkwo O; Li L
ACS Chem Biol; 2022 Nov; 17(11):3059-3068. PubMed ID: 34964596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
